Trial: 202006003

A Phase 1b, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in Combination with Axitinib in Subjects with Advanced Renal Cell Carcinoma

Phase

I

Principal Investigator

Picus, Joel

Disease Site

Kidney

Learn more about this study at: clinicaltrials.gov